GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (LTS:0VGI) » Definitions » Tax Rate %

TG Therapeutics (LTS:0VGI) Tax Rate % : 8.34% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is TG Therapeutics Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. TG Therapeutics's Tax Expense for the three months ended in Dec. 2024 was $2.1 Mil. TG Therapeutics's Pre-Tax Income for the three months ended in Dec. 2024 was $25.5 Mil. Therefore, TG Therapeutics's Tax Rate % for the quarter that ended in Dec. 2024 was 8.34%.

TG Therapeutics Tax Rate % Historical Data

The historical data trend for TG Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TG Therapeutics Tax Rate % Chart

TG Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 2.99 8.64

TG Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.78 -0.27 -5.01 9.09 8.34

TG Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

TG Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2024 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2024 )/Pre-Tax Income (A: Dec. 2024 )
=2.211/25.594
=8.64 %

TG Therapeutics's Tax Rate % for the quarter that ended in Dec. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2024 )/Pre-Tax Income (Q: Dec. 2024 )
=2.122/25.453
=8.34 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TG Therapeutics Tax Rate % Related Terms

Thank you for viewing the detailed overview of TG Therapeutics's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

TG Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TG Therapeutics Inc (LTS:0VGI) » Definitions » Tax Rate %
Comparable Companies
IONS SWTX KRYS CRSP NUVL AKRO RARE PTCT VKTX ADMA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
TGTX:USA NKB2:Germany NKB2:Germany
Address
3020 Carrington Mill Boulevard, Suite 475, Morrisville, NC, USA, 27560
Website
https://www.tgtherapeutics.com
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Headlines

No Headlines